Similarly, studies of the hereditary pRCC syndromes identified germline activating mutations within the MET oncogene in hereditary papillary renal carcinoma (HPRC), associated with type 1 pRCC, as well as germline inactivating mutations in the FH tumor suppressor gene in hereditary leiomyomatosis and renal cell carcinoma (HLRCC), often associated with an aggressive variant of type 2 pRCC.10, 11, 12. This evidence concerns the gene FH and hereditary leiomyomatosis and renal cell cancer.